AM630 is an inverse agonist at the human cannabinoid CB1 receptor

Life Sciences

Volumn 62, Issue 9, 1998, Pages

  Landsman, Robert S ^a   Makriyannis, Alexandros ^b   Deng, Hongfeng ^b   Consroe, Paul ^a   Roeske, William R ^a   Yamamura, Henry I ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

AM630; CHO cells; GTP S; Human cannabinoid CB1 receptor; Inverse agonism; Inverse agonist; Negative intrinsic activity; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID RECEPTOR; FOSFAZINOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HAMSTER; NONHUMAN;

ANIMALS; CELL MEMBRANE; CHO CELLS; CRICETINAE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INDOLES; MORPHOLINES; NAPHTHALENES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RECOMBINANT PROTEINS;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS;

EID: 4243447225     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01187-9     Document Type: Article

References (12)

1. 1. R.G. PERTWEE, G. GRIFFIN, S. FERNANDO, X. LI, A. HILL and A. MAKRIYANNIS, Life Sci. 56 1949-1955 (1995).
2. 2. R.G. PERTWEE, S.R. FERNANDO, J.E. NASH and A.A. COUTTS, J. Pharmacol. 118 2199-2205 (1996).
3. 3. K. HOSOHATA, R.M. QUOCK, Y. HOSOHATA, T.H. BURKEY, A. MAKRIYANNIS, P. CONSROE, W.R. ROESKE and H.I. YAMAMURA, Life Sci., 61 PL 115-PL 118 (1997).
4. 4. J.R. TRAYNOR and S.R. NAHORSKI, Mol. Pharmacol. 47 848-854 (1995).
5. 5. O.H. LOWRY, N.J. ROSEBROUGH, A.L. FARR and R.J. RANDALL, J. Biol. Chem. 193 265-275 (1951)
6. 6. M. PACHECO, S.R. CHILDERS, R. ARNOLD, F. CASIANO and S.J. WARD, J. Pharmacol. Exp. Ther. 257 170-183 (1991).
7. 7. D.R. COMPTON, L.H. GOLD, S.J. WARD, R.J. BALSTER and B.R. MARTIN, J. Pharmacol. Exp. Ther. 263 1118-1126 (1992).
8. 8. D.R. COMPTON, M.D. ACETO, J. LOWE and B.R. MARTIN, J. Pharmacol. Exp. Ther. 277 586-594 (1996).
9. 9. J.D. RICHARDSON, L. AANONSEN and K.M. HARGREAVES, Eur. J. Pharmacol. 319 R3-R4 (1997).
10. 10. J.P. TERRANOVA, J.J. STORME, N. LAFON, A. PERIO, M. RINALDI-CARMONA, G. LE FUR and P. SOUBRIE, Psychopharmacology 126 165-172 (1996).
11. 11. M. BOUABOULA, S. PERRACHON, L. MILLIGAN, X. CANAT, M. RINALDI-CARMONA, M. PORTIER, F. BARTH, B. CALANDRA, F. PECCEU, J. LUPKER, J-P. MAFFRAND, G. LE FUR and P. CASELLAS, J. Biol. Chem. 272 22330-22339 (1997).
12. 12. R.S. LANDSMAN, T.H. BURKEY, P. CONSROE, W.R. ROESKE and H.I. YAMAMURA, Eur. J. Pharmacol. 334 R1-R2 (1997).